CCS adapting to COVID-19 realities to support Canadians during and after the pandemic
Dr Michael Ohh
Bernard and Francine Dorval Prize co-recipient in 2010
Dr Ohh is an associate professor in the department of laboratory medicine and pathobiology at the University of Toronto. He is known for his paradigm-shifting work in the field of oxygen-sensing pathways in cancer development and progression. His work of deciphering these pathways at cellular and molecular levels has led to innovations in novel anti-cancer therapies. His laboratory is also an excellent training ground for graduate students, postdoctoral fellows and clinician-scientists interested in basic cancer biology and translational research.
Dr Ohh received his PhD from the University of British Columbia in 1995 and was a Medical Research Council (CIHR) and National Cancer Institute of Canada postdoctoral fellow at the Dana-Farber Cancer Institute at Harvard Medical School prior to joining University of Toronto. He holds a Canada Research Chair in Molecular Oncology.
Dr Ohh has published over 50 peer-reviewed papers in high-impact journals such as Nature Medicine and Science with over 5,000 combined citations. He is frequently invited to present his concept-provoking ideas and findings at both basic research and clinical meetings in Canada, the United States and Europe. combined citations. He is frequently invited to present his concept-provoking ideas and findings at both basic research and clinical meetings in Canada, the United States and Europe.
Investing to reduce cancer burden
Last year CCS funded $40 million in cancer research, thanks to our donors. Discover how you can help reduce the burden of cancer.